CME/CE Accreditation Information Return to Previous

Strategies for Improving Outcomes in CAR T-cell Therapy for DLBCL


Although many patients with diffuse large B-cell lymphoma (DLBCL) are achieve remission with first-line treatment, the disease relapses in 30% to 40% of patients, and 10% of patients show primary refractory disease. Three CD19-directed chimeric antigen receptor (CAR) T-lymphocyte (T-cell) therapy products are currently approved by the US Food and Drug Administration (FDA) for the treatment of R/R DLBCL after failure of 2 or more prior lines of therapy. 

Choosing the most appropriate CD19-directed CAR T-cell therapy for patients with R/R DLBCL can be challenging for clinicians as no head-to-head clinical trials are available and because a multitude of clinical and product factors raise various barriers to their broader access and use. Because of their associated risks of severe and life-threatening toxicities, CD19-directed CAR T-cell therapies require appropriate dosing, frequent monitoring, and prompt management of adverse effects (AEs), all of which can be challenging for clinicians and require close collaboration with patients to improve adherence to treatment plans.

Community-based clinicians desire to, and will eventually, treat patients by using CAR T-cell therapy in the future. Expert education to successfully manage patients apart from a specialty center is crucial.


At the conclusion of this activity, participants should be better able to: 

  • Interpret clinical efficacy and safety data surrounding current and emerging CD19-directed CAR T-cell therapies for relapsed or refractory DLBCL
  • Select appropriate CD19-directed CAR T-cell therapeutic options for patients with relapsed or refractory DLBCL
  • Implement evidence-based strategies to dose, monitor, and manage adverse effects of CD19-directed CAR T-cell therapies in patients with DLBCL


Hematologists, oncologists, pharmacists, nurse practitioners, physician associates, nurses, and other members of a multidisciplinary clinical team for patients with lymphomas


Supported by an educational grant from Bristol Myers Squibb


Accredited by

In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.





Credit Designation Statement


IPCE credits

This activity was planned by and for the healthcare team, and learners will receive 3.5 Interprofessional Continuing Education (IPCE) credits for learning and change.



AMA PRA Category 1 Credits TM

Haymarket Medical Education designates this enduring activity for a maximum of 3.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



ANCC Contact Hours

This activity is awarded 3.5 contact hours (based on 60 minutes per contact hour).



ACPE Continuing Pharmacy Education Credits

This knowledge-based activity JA4008232-0000-22-037-H01-P

qualifies for 3.50 contact hours 3.50 CEUs of continuing pharmacy education credit.


Haymarket Medical Education adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


This IPCE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this IPCE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Bristol Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact


Frederick L. Locke, MD
Leader, Cellular Immunotherapy Program
Co-Leader, Immuno-Oncology Program
Chair and Associate Member, Department of Blood and Marrow
Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, FL

Dr. Locke has disclosed the following financial relationships:
Scientific Advisory Role: A2 Bio, Allogene Therapeutics, Amgen Inc., bluebird bio Inc., Bristol Myers Squibb/Celgene, Calibr, Caribou, Cellular Biomedicine Group, Inc., Daiichi Sankyo, Inc., GammaDelta Therapeutics Limited, Iovance Biotherapeutics, Janssen Pharmaceuticals, Inc., Kite Pharma/Gilead Sciences, Inc., Legend Biotech, Novartis Pharmaceuticals Corp., Sana Biotechnology, Takeda Pharmaceutical Company, Umoja Biopharma, and Wugen. 

Research Funding: Allogene Therapeutics (Institutional), bluebird bio Inc. (Institutional), Bristol Myers Squibb (Institutional), CERo Therapeutics, Inc. (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society, National Cancer Institute, and Novartis Pharmaceuticals Corp. (Institutional).  

Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. 

Consulting Role: Cowen, EcoRl, Emerging Therapy Solutions, Inc., and Gerson Lehrman Group (GLG) 

Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, lmedex, LLC., and the Society for Immunotherapy of Cancer.


Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, NY


Dr. Salles has disclosed the following financial relationships:

Advisory Board/Consulting: AbbVie Inc., Bayer, BeiGene USA, Inc., Bristol Myers Squibb/Celgene, Epizyme, Inc., Genentech, Inc./Roche, Genmab, Incyte Corp., Ipsen Biopharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma/Gilead Sciences, Inc., Loxo Oncology, Milteniy Biomedicine, Molecular Partners,  MorphoSys US, Inc., Nordic Nanovector ASA, Novartis Pharmaceuticals Corp., Rapt Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceutical Company.

All of the relevant financial relationships listed for these individuals have been mitigated.

None of the planners, reviewers, and Haymarket Medical Education staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.